Showing 1311-1320 of 1484 results for "".
- Bio-Tissue Expands National Footprint, Ramps Up Sales Force by More than 25 Percenthttps://modernod.com/news/bio-tissue-expands-national-footprint-ramps-up-sales-force-by-more-than-25-percent/2479535/Bio-Tissue, a subsidiary of TissueTech, announced the expansion of its sales force to more effectively meet the needs of clinicians and their patients. “A growing body of scientific evidence has cemented CAM as a mainstay treatment for ocular surface diseases,” Grady Grant III, TissueTech
- New Accessible Products Hotline to Offer Advice on Products for Blind or Visually Impairedhttps://modernod.com/news/new-accessible-products-hotline-to-offer-advice-on-products-for-blind-or-visually-impaired/2476823/Envision has launched a first-of-its-kind Accessible Products Hotline that aims to help consumers with vision loss find products that fit their unique accessibility needs. Funded by a grant from the Consumer Technology Association (CTA) Foundation, the hotline will be operated by the William L. H
- AcuFocus Completes Study Enrollment for U.S. IDE Clinical Trial of IC-8 Lenshttps://modernod.com/news/acufocus-completes-study-enrollment-for-u-s-ide-clinical-trial-of-ic-8-lens/2476806/AcuFocus announced that it has completed enrollment in its pivotal US investigational device exemption (IDE) study of the company’s IC-8 small aperture IOL. FDA granted approval of the company’s IDE on November 21, 2018, and the Investigational Review Board approved the study just 5
- Post-Approval Study Finds No Surprises With Argus II Retinal Implanthttps://modernod.com/news/post-approval-study-finds-no-surprises-with-argus-ii-retinal-implant/2476647/Post-approval follow-up of the Argus II Retinal Prosthesis System shows safety and visual function outcomes similar to those in previous trials, according to a company-funded study, as reported in Reuters. With a CE mark granted in 2011, the device became the first retinal prosthesis to b
- Ophtec’s Preloaded Capsular Tension Ring Ringject Receives Approval in Chinahttps://modernod.com/news/ophtecs-preloaded-capsular-tension-ring-ringject-receive-approval-in-china/2476275/Ophtec was granted CFDA approval for the preloaded capsular tension ring (CTR) Ringject in China. Ringject is a preloaded, single use capsular tension ring designed to be self-loading for surgical convenience. CTRs were originally introduced to strengthen the zonule in eyes with zonular de
- Ophtec’s Precizon Presbyopic IOL with Continuous Transitional Focus (CTF) Optic Now Patented in the UShttps://modernod.com/news/ophtecs-precizon-presbyopic-iol-with-continuous-transitional-focus-ctf-optic-now-patented-in-the-us/2476299/Ophtec was granted a patent by the US patent office for its Continuous Transitional Focus (CTF) optical design of the new aspheric presbyopia correcting IOL. This new generation of multifocal IOLs for the treatment of cataracts, called “Precizon Presbyopic,” allows patients to experie
- Avedro Launches Initial Public Offeringhttps://modernod.com/news/avedro-launches-initial-public-offering/2476317/Avedro announced that it has commenced an initial public offering of 5 million shares of common stock. The initial public offering price is currently estimated to be between $14 and $16 per share. Avedro expects to grant the underwriters a 30-day option to purchase up to an additional 750,000 sha
- Leica Biosystems Receives US Patent for RTF Extreme Speed Scanning Technologyhttps://modernod.com/news/leica-biosystems-receives-us-patent-for-rtf-extreme-speed-scanning-technology/2476211/Leica Biosystems announced that the US Patent Office has granted it a patent for RTF, its “Real-Time Focusing” technology (US patent 9,841,590). Leica says this will enable high volume, extremely fast line scanning of anatomic pathology slides. “RTF technology dramaticall
- Oculogica Receives FDA Marketing Approval for EyeBOX, the First Noninvasive, Baseline-Free Test for Concussionhttps://modernod.com/news/oculogica-receives-fda-marketing-approval-for-eyebox-the-first-noninvasive-baseline-free-test-for-concussion/2476218/Oculogica announced that the FDA granted their De Novo request for the commercialization of EyeBOX, the first noninvasive, baseline-free tool to aid in the diagnosis of concussion. Oculogica plans to market the device for use in pediatrics ages 5 and older and adults up to 67 years o
- Chugai’s Satralizumab Receives FDA Breakthrough Therapy Designation for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disordershttps://modernod.com/news/chugais-satralizumab-receives-fda-breakthrough-therapy-designation-for-neuromyelitis-optica-and-neuromyelitis-optica-spectrum-disorders/2476249/Japan-based Chugai Pharmaceutical announced that the FDA has granted breakthrough therapy designation for Chugai’s anti-interleukin-6 (IL-6) receptor humanized recycling antibody satralizumab, an investigational medicine for neuromyelitis optica and neuromyelitis optica spectrum disorders (NMO/NM